Patents Assigned to Merck
  • Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
    Patent number: 10059705
    Abstract: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: August 28, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher Dinsmore, Peter Fuller, David Guerin, Jason David Katz, Christopher F. Thompson, Danielle Falcone, Wei Deng, Luis Torres, Hongbo Zeng, Yunfeng Bai, Jianmin Fu, Norman Kong, Yumei Liu, Zhixiang Zheng, Mark E. Scott
  • Antidiabetic compounds
    Patent number: 10059667
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: August 28, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Harry Chobanian, Duane DeMong, Yan Guo, Zhiyong Hu, Michael Miller, Barbara Pio, Christopher W. Plummer, Dong Xiao, Cangming Yang
  • TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS
    Publication number: 20180237422
    Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: March 11, 2016
    Publication date: August 23, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dong-Ming Shen, Christopher J. Sinz, Alejandro Crespo, Johnathan E. Wilson, Troy McCraken, Shimin XU, Haitang Li
  • CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
    Publication number: 20180237469
    Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Application
    Filed: February 1, 2018
    Publication date: August 23, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, Andrew Marc Haidle, Timothy J. Henderson, James P. Jewell, Rui Liang, Jongwon Lim, Hong Liu, Min Lu, Alan B. Northrup, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Quang T. Truong, Shawn P. Walsh, Kake Zhao
  • CRYSTALS OF ANTI-HUMAN PD-1 MONOCLONAL ANTIBODIES
    Publication number: 20180237524
    Abstract: Crystals of pembrolizumab and structurally similar anti-PD-1 monoclonal antibodies are provided, as well as methods of producing such crystals, and uses of compositions comprising such antibody crystals, e.g. in treatment of cancers. The present invention satisfies these needs and more by providing pembrolizumab crystals and a method producing pembrolizumab crystals. One embodiment of the method of the invention produces crystals suitable for X-ray diffraction, and the inventors herein used such crystals to solve the three-dimensional structure of pembrolizumab to 2.3 A resolution.
    Type: Application
    Filed: February 22, 2016
    Publication date: August 23, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Paul Reichert, Winifred W. Prosise, Giovanna Scapin, Xiaoyu Yang, Ramesh Kashi, Corey Strickland
  • PHENOXAZINE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES
    Publication number: 20180240983
    Abstract: The present invention relates to the compounds of the formulae (1) and (2) and to organic electroluminescent devices, in particular blue-emitting devices, in which these compounds are used as host material or dopant in the emitting layer and/or as hole-transport material and/or as electron-transport material.
    Type: Application
    Filed: July 15, 2016
    Publication date: August 23, 2018
    Applicant: Merck Patent GmbH
    Inventors: Holger Heil, Beate Burkhart, Lara-Isabel Rodriguez, Sebastian Meyer, Rouven Linge
  • MATERIALS FOR ELECTRONIC DEVICES
    Publication number: 20180240985
    Abstract: The present application relates to compounds of a formula (I), to the use thereof in organic electroluminescent devices, and to processes for preparing these compounds.
    Type: Application
    Filed: July 13, 2016
    Publication date: August 23, 2018
    Applicant: Merck Patent GmbH
    Inventors: Lara-Isabel Rodriguez, Linge Rouven, Sebastian Meyer, Holger Heil, Beate Burkhart
  • GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS
    Publication number: 20180237856
    Abstract: The present invention provides genetic markers on human chromosome 1 that are associated with a beneficial response to CRTH2 receptor antagonists. These CRTH2 receptor antagonist response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with CRTH2 receptor antagonist compositions and drug products, in methods of treating patients having a disease susceptible to treatment with a CRTH2 receptor antagonist, and in methods for selecting the most appropriate therapy for such patients.
    Type: Application
    Filed: July 21, 2016
    Publication date: August 23, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gregory J. Opiteck, Peggy H. Wong, Joshua McElwee, Devan V. Mehrotra, Steven Greenberg, Zifang Guo
  • COMPOUNDS FOR OPTICALLY ACTIVE DEVICES
    Publication number: 20180237409
    Abstract: The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for ophthalmic devices as well as to ophthalmic devices comprising such compounds.
    Type: Application
    Filed: August 3, 2016
    Publication date: August 23, 2018
    Applicant: Merck Patent GmbH
    Inventors: Lars DOBELMANN-MARA, Stefan RIEDMUELLER, Martin SCHRAUB
  • MATERIAL COMBINATION
    Publication number: 20180237696
    Abstract: The invention relates to a material combination comprising a first fluid comprising a liquid crystal material, and an electrically insulating second fluid substantially not miscible with the first fluid, and to an optical device using the same.
    Type: Application
    Filed: July 14, 2016
    Publication date: August 23, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: Rachel TUFFIN, Owain Llyr PAARI, Philip BAKER, Carl BROWN, Ian Charles SAGE
  • HYDROPHILIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES
    Publication number: 20180237410
    Abstract: The present invention relates to novel compounds, particularly to hydrophilic compounds, comprising a photoactive unit, said novel compounds being particularly suitable for ophthalmic devices. The present application also relates to ophthalmic devices comprising such compounds.
    Type: Application
    Filed: August 3, 2016
    Publication date: August 23, 2018
    Applicant: Merck Patent GmbH
    Inventors: Lars DOBELMANN-MARA, Stefan RIEDMUELLER, Martin SCHRAUB
  • Anti-coagulation factor XI antibodies
    Patent number: 10053515
    Abstract: Antibodies that bind the apple 2 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa are described.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: August 21, 2018
    Assignees: Merck Sharp & Dohme Corp., Adimab LLC
    Inventors: Zhu Chen, Kenneth P. Ellsworth, James A. Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
  • Conjugated polymers
    Patent number: 10053542
    Abstract: The invention relates to novel conjugated polymers containing one or more polycyclic repeating units, to methods for their preparation and educts or intermediates used therein, to polymer blends, mixtures and formulations containing them, to the use of the polymers, polymer blends, mixtures and formulations as organic semiconductors in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to OE, OPV and OPD devices comprising these polymers, polymer blends, mixtures or formulations.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: August 21, 2018
    Assignee: Merck Patent GmbH
    Inventors: William Mitchell, Changsheng Wang, Nicolas Blouin, Mansoor D'Lavari, Jingyao Song
  • Emitter and hosts with aromatic units
    Patent number: 10056548
    Abstract: The invention concerns polymers, electroluminescence devices, compositions and their use.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: August 21, 2018
    Assignee: Merck Patent GmbH
    Inventors: Junyou Pan, Martin Engel, Nils Koenen, Aurélie Ludemann
  • Compounds for electronic devices
    Patent number: 10056549
    Abstract: The present invention relates to a compound of the formula (I), to the use of the compound in an electronic device, and to an electronic device comprising a compound of the formula (I). The present invention furthermore relates to a process for the preparation of a compound of the formula (I) and to a formulation comprising one or more compounds of the formula (I).
    Type: Grant
    Filed: April 14, 2012
    Date of Patent: August 21, 2018
    Assignee: Merck Patent GmbH
    Inventors: Elvira Montenegro, Arne Buesing, Frank Voges, Christof Pflumm
  • Purification device for a liquid-crystal mixture
    Patent number: 10052566
    Abstract: A purification device (1), for the purification of a liquid-crystal mixture, has a flow chamber (2) which has an inlet opening (3) and an outlet opening (4), arranged opposite the inlet opening, in order to be able to introduce the liquid-crystal mixture into the flow chamber (2) and discharge it from the latter, and at least one flow distribution element (5) which is arranged in the flow chamber (2) in the region of the inlet opening (3), and at least one filter element (6) which is arranged in the region of the outlet opening (4), where a length of the flow chamber (2) measured in the flow direction is at least a factor of 2 greater than a greatest internal dimension of the flow chamber (2) transverse to the flow direction.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: August 21, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Guenter Hauke, Sebastien Marie, Leticia Garcia Diez, Michael Ukelis, Andreas Beirau, Michael Haeberl
  • Process for preparing chiral dipeptidyl peptidase-IV inhibitors
    Patent number: 10053466
    Abstract: A process for preparing a compound of structural Formula Ia: comprising Boc deprotection with TFA of: ?and reductive amination of:
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: August 21, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Feng Peng, Yonggang Chen, Amude Mahmoud Kassim, Cheng-yi Chen, Mathew Maust, Mark McLaughlin, Michael J. Zacuto, Qinghao Chen, Lushi Tan, Zhiguo Jake Song, Yang Cao, Feng Xu
  • Methods and compositions for treating cancer by identifying one or more ERK mutations
    Patent number: 10053737
    Abstract: The invention is directed to methods, reagents, and kits for the detection of MAPK/ERK pathway mutations in a patient diagnosed for cancer. In one embodiment, the invention comprises a sensitive and selective method to identify mutations to the BRAF, KRAS, and NRAS genes in a single reaction. In another aspect of this embodiment, the invention comprises primers and probes for the detection of the BRAF, KRAS, and NRAS mutations using a single nucleotide primer extension assay. In another embodiment the invention is used to identify and select patients amenable for treatment with an ERK inhibitor.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: August 21, 2018
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Ken C. N. Chang, Stefan Galuska, Matthew J. Marton
  • Process for the preparation of tert-butyl 4-((2S ,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate and analogs thereof
    Patent number: 10053460
    Abstract: The present invention relates to processes for preparing compounds of Formula I. Such compounds include interme-diates in the manufacture of 7-oxo-1,6-diazabicyclo[3.2.1 ]octane-2-carboxamide beta-lactamase inhibitors such as (2S,5R)-7-oxo-N-5 piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide. The present invention also relates to novel intermediates formed i these processes. The present invention relates to a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: August 21, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Zhijian Liu, Nobuyoshi Yasuda, Lu Yang, Artis Klapars, Kevin R. Campos, Mikhail Reibarkh
  • Water purifier cartridge
    Patent number: D826375
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: August 21, 2018
    Assignee: Merck Patent GmbH
    Inventors: Christian Berducat, Eric Biget, Katharine Molders